Concepedia

Author

Jenifer Wogen

Novartis (United States)

Also Known As

Aaron Winn, J WOGEN, J. Wogen, James Wilson, Jenifer Wogen, Wogen, Jenifer

36

Publications

949

Citations

13

H-Index

10

Concepts

All Affiliations

Novartis (United States)Towa Pharmaceutical (Japan)
JW

About

Jenifer Wogen is an author at Novartis (United States) specializing in digestive system diseases, pharmacoepidemiology, and health policy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

31

2

Gastroenterology

1

1

31

3

Health Policy

1

1

31

4

Pharmacology

1

1

31

5

Clinical Effectiveness

1

1

31

Jenifer Wogen

×

16

Publications

879

Citations

13

H-Index

YearCitations

Utilization of Oral Hypoglycemic Agents in a Drug-Insured U.S. Population

Stephen J. Boccuzzi, Jenifer Wogen, James M. Fox,

Diabetes Care

2001

181

Adherence to Prescribed Treatment for Asthma: Evidence from Pharmacy Benefits Data

Craig Jones, Nancy C. Santanello, Steve J. Boccuzzi,

Journal of Asthma

2003

132

Human Rights, Stigma, and Substance Use.

Jenifer Wogen, Maria Teresa Restrepo

PubMed

2020

97

Loss of Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Were Receiving Initial Metformin, Sulfonylurea, or Thiazolidinedione Monotherapy

Aylin Riedel, Herbert C. Heien, Jenifer Wogen,

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

2007

79

Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs

Ann K. Wittkowsky, Stephen J. Boccuzzi, Jenifer Wogen,

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

2004

77

Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin

Lawrence Blonde, Jenifer Wogen, C. Kreilick,

Diabetes Obesity and Metabolism

2003

75

Identifying Barriers to Hypertension Care: Implications for Quality Improvement Initiatives

Nan L. Holland, Denise Segraves, Victoria O. Nnadi,

Disease Management

2008

54

Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.

Aylin Riedel, Herbert C. Heien, Jenifer Wogen,

PubMed

2007

35

Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.

Loren Laine, Jenifer Wogen, Holly Yu

Gastroenterology

2003

31

Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States

Daniel Belletti, Christopher Zacker, Jenifer Wogen

Cardiovascular Diabetology

2010

30

Page 1